Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Ciclosporin compared to prednisolone therapy for patients with pyoderma gangrenosum : cost-effectiveness analysis of the STOP GAP trial

Tools
- Tools
+ Tools

Mason, James, Thomas, K. S., Ormerod, A. D., Craig, F. E., Mitchell, E., Norrie, J. and Williams, H. C. (2017) Ciclosporin compared to prednisolone therapy for patients with pyoderma gangrenosum : cost-effectiveness analysis of the STOP GAP trial. British Journal of Dermatology . doi:10.1111/bjd.15561 ISSN 0007-0963.

[img]
Preview
PDF
WRAP-ciclosporin-prednisolone-patients-pyoderma-gangrenosum-Mason-2017.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons: Attribution-Noncommercial 4.0.

Download (640Kb) | Preview
[img] PDF
WRAP-ciclosporin-compared-prednisolone-Mason-2017.pdf - Accepted Version
Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer.

Download (352Kb)
Official URL: http://dx.doi.org/10.1111/bjd.15561

Request Changes to record.

Abstract

Background:

Pyoderma gangrenosum (PG) is a painful, ulcerating skin disease with poor evidence for management. Prednisolone and ciclosporin are the most commonly used treatments, although not previously compared within a randomised controlled trial (RCT)

Objectives:

To compare the cost-effectiveness of ciclosporin and prednisolone-initiated treatment for patients with PG.

Methods:

Quality-of-life (EuroQoL EQ-5D-3L) and resource data were collected as part of the STOP-GAP trial: a multicentre, parallel-group, observer-blind RCT. Within-trial analysis used bivariate regression of costs and QALYs, with multiple imputation of missing data, informing a probabilistic assessment of incremental treatment cost-effectiveness from a health service perspective.

Results:

In the base case analysis, when compared with prednisolone, ciclosporin was cost-effective due to a reduction in costs (net cost: -£1160; 95%CI: (-2991 to 672) and improvement in quality of life (net QALYs: 0.055; 95%CI: 0.018 to 0.093). However, this finding appears driven by a minority of patients with large lesions (≥20cm2) (net cost: -£5310; 95%CI: -9729 to -891; net QALYs: 0.077; 95%CI: 0.004 to 0.151). The incremental cost-effectiveness of ciclosporin for the majority of patients with smaller lesions was £23,374/QALY although the estimate is imprecise: the probability of being cost-effective at a willingness to pay of £20,000/QALY was 43%.

Conclusions:

Consistent with the clinical findings of the STOP-GAP trial, patients with small lesions should receive treatment guided by the side effect profiles of the drugs and patient preference - neither strategy is clearly a preferred use of NHS resources. However, ciclosporin-initiated treatment may be more cost-effective for patients with large lesions.

Item Type: Journal Article
Subjects: R Medicine > RL Dermatology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Pyoderma -- Treatment -- Cost effectiveness
Journal or Publication Title: British Journal of Dermatology
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 0007-0963
Official Date: 9 April 2017
Dates:
DateEvent
9 April 2017Available
5 April 2017Accepted
DOI: 10.1111/bjd.15561
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 12 April 2017
Date of first compliant Open Access: 1 June 2017
Funder: National Institute for Health Research (Great Britain). Applied Research Programme (ARP NIHR)
Grant number: RP-PG-0407-10177
Contributors:
ContributionNameContributor ID
Research GroupThe UK Dermatology Clinical Trials Network , STOP GAP teamUNSPECIFIED

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us